Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
by Zacks Equity Research
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
Stock Market News For Jul 9, 2018
by Zacks Equity Research
Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
Top Analyst Reports for Johnson & Johnson, Biogen & General Motors
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM).
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
PTC Therapeutics' Spinal Muscular Atrophy Study Successful
by Zacks Equity Research
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
by Zacks Equity Research
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
Drug Stocks: The Next Hot Industry or Value Traps?
by Tracey Ryniec
These 5 stocks look dirt cheap but is it too good to be true?
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
by Zacks Equity Research
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
by Zacks Equity Research
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.